scholarly journals Re-evaluation of the predictive score for 6-month graft survival in living donor liver transplantation in the modern era

2014 ◽  
Vol 20 (3) ◽  
pp. 323-332 ◽  
Author(s):  
Tomoharu Yoshizumi ◽  
Toru Ikegami ◽  
Yuki Bekki ◽  
Mizuki Ninomiya ◽  
Hideaki Uchiyama ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Graft Survival ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Predictive Score ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Modern Era

scholarly journals Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Steffen Hartleif ◽  
Michael Schumm ◽  
Michaela Döring ◽  
Markus Mezger ◽  
Peter Lang ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Graft Survival ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Immunosuppressive Treatment ◽  
Pilot Trial ◽  
High Dose ◽  
Donor Liver ◽  
Open Label ◽  
Donor Liver Transplantation

Background. Calcineurin inhibitors (CNI) have significantly improved patient and graft survival in pediatric liver transplantation (pLT). However, CNI toxicity leads to significant morbidity. Moreover, CNIs cannot prevent long-term allograft injury. Mesenchymal stem (stromal) cells (MSC) have potent immunomodulatory properties, which may promote allograft tolerance and ameliorate toxicity of high-dose CNI. The MYSTEP1 trial aims to investigate safety and feasibility of donor-derived MSCs in pLT. Methods/Design. 7 to 10 children undergoing living-donor pLT will be included in this open-label, prospective pilot trial. A dose of 1 × 106 MSCs/kg body weight will be given at two time points: first by intraportal infusion intraoperatively and second by intravenous infusion on postoperative day 2. In addition, participants will receive standard immunosuppressive treatment. Our primary objective is to assess the safety of intraportal and intravenous MSC infusion in pLT recipients. Our secondary objective is to evaluate efficacy of MSC treatment as measured by the individual need for immunosuppression and the incidence of biopsy-proven acute rejection. We will perform detailed immune monitoring to investigate immunomodulatory effects. Discussion. Our study will provide information on the safety of donor-derived MSCs in pediatric living-donor liver transplantation and their effect on immunomodulation and graft survival.

scholarly journals Association between neutrophil–lymphocyte ratio change during living donor liver transplantation and graft survival

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jungchan Park ◽  
Seung-Hwa Lee ◽  
Mi Sook Gwak ◽  
Justin Sangwook Ko ◽  
Sangbin Han ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Graft Survival ◽  
Graft Failure ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio

AbstractPreoperative neutrophil–lymphocyte ratio (NLR), has shown a predictive value in living donor liver transplantation (LDLT). However, the change in the NLR during LDLT has not been fully investigated. We aimed to compare graft survival between the NLR increase and decrease during LDLT. From June 1997 to April 2019, we identified 1292 adult LDLT recipients with intraoperative NLR change. The recipients were divided according to NLR change: 103 (8.0%) in the decrease group and 1189 (92.0%) in the increase group. The primary outcome was graft failure in the first year. In addition, variables associated with NLR change during LDLT were evaluated. During 1-year follow-up, graft failure was significantly higher in the decrease group (22.3% vs. 9.1%; hazard ratio 1.87; 95% confidence interval 1.10–3.18; p = 0.02), but postoperative complications did not differ between two groups. This finding was consistent for the overall follow-up. Variables associated with NLR decrease included preoperative NLR > 4, model for end-stage liver disease score, intraoperative inotropic infusion and red blood cell transfusion, and operative duration. The least absolute shrinkage and selection operator model yielded similar results. NLR decrease during LDLT appeared to be independently associated with graft survival. Further studies are needed to confirm our findings.

(D+10) MELD as a novel predictor of patient and graft survival after adult to adult living donor liver transplantation

2017 ◽  
Vol 31 (5) ◽  
pp. e12939 ◽  
Author(s):  
Arvinder Singh Soin ◽  
Sanjay Goja ◽  
Sanjay Kumar Yadav ◽  
Tseten Yonjen Tamang ◽  
Amit Rastogi ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Graft Survival ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Patient And Graft Survival

scholarly journals Impact of Early Reoperation following Living-Donor Liver Transplantation on Graft Survival

PLoS ONE ◽  
2014 ◽  
Vol 9 (11) ◽  
pp. e109731 ◽  
Author(s):  
Yoshikuni Kawaguchi ◽  
Yasuhiko Sugawara ◽  
Nobuhisa Akamatsu ◽  
Junichi Kaneko ◽  
Tsuyoshi Hamada ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Graft Survival ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Early Reoperation

scholarly journals Impact of preoperative portal vein thrombosis on the outcome of living donor liver transplantation

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
M F Abdelghaffar ◽  
M A Rady ◽  
K M Kamal ◽  
M A Mahgoub
Keyword(s):  
Liver Transplantation ◽  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Graft Survival ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Survival Rates ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Vein Thrombosis

Abstract Background Portal vein thrombosis (PVT) is a common complication in terminal-stage liver disease. Its incidence in liver transplantation (LT) ranges from 2.1% to 26%. In the past, PVT was considered an absolute contraindication for LT, especially due to the technical difficulty involved. Nonetheless, since the mid-1980s, with the introduction of new surgical techniques, PVT is no longer considered an absolute contraindication in a larger percentage of patients. Aim of the Work to show the effect of preoperative portal vein thrombosis with its different extension degree on both patient and graft survival post living donor liver transplantation. Patients and Methods This retrospective cohort study was conducted on all the patients who performed living donor liver transplantation during the period from January 2010 till June 2017 at Ain Shams centre for organ transplantation (ASCOT). Our study included 240 cases who performed right lobe LDLT in that time interval and fulfilled the required data and time interval follow up. Those 240 cases were classified into 2 groups: group A Patients without preoprative PVT (200); group B Patients with pre-operative PVT. (40). Results 1-year patients survival rates of patients with and without PVT were 75% vs. 85%. t 2-year patients survival rates of patients with and without PVT 75% vs. 84%. 1-year graft survival rates of patients with and without PVT were 75% vs. 84%; that 2-year graft survival rates of patients with and without PVT: 65% vs. 77%. Conclusion P.V.T not only makes the surgery more difficult and complex but it also affects the outcome of LT. However Further studies should be done taking in consideration different degree of extension of the thrombus as it has crucial effect on the outcome of the liver transplantation.

Factors affecting graft survival after living donor liver transplantation

2004 ◽  
Vol 36 (8) ◽  
pp. 2255-2256 ◽  
Author(s):  
D.S. Lee ◽  
W.H. Gil ◽  
H.H. Lee ◽  
K.W. Lee ◽  
S.K. Lee ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Graft Survival ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Donor Liver ◽  
Factors Affecting ◽  
Donor Liver Transplantation
Sign in / Sign up

Export Citation Format

Share Document